How to buy InMed Pharmaceuticals stock | $2.95

InMed Pharmaceuticals Inc is a biotechnology business based in the US. InMed Pharmaceuticals shares (INM) are listed on the NASDAQ and all prices are listed in US Dollars.

InMed Pharmaceuticals stock price (NASDAQ: INM)

Use our graph to track the performance of INM stocks over time.

InMed Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$2.95
52-week range	$2.38 - $5.66
50-day moving average	$2.83
200-day moving average	$3.55
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy InMed Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy InMed Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of InMed Pharmaceuticals Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

InMed Pharmaceuticals price performance over time

Historical closes compared with the close of $2.95 from 2021-05-28

1 week (2021-07-25)	N/A
1 month (2021-07-02)	-7.52%
3 months (2021-05-05)	-17.60%
6 months (2021-02-01)	N/A

1 year (2020-08-01)	N/A
2 years (2019-08-01)	N/A
3 years (2018-08-01)	N/A
5 years (2016-08-01)	N/A

InMed Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-52.16%
Return on equity TTM	-105.12%
Profit margin	0%
Book value	$1.29
Market capitalisation	$24.1 million

TTM: trailing 12 months

Shorting InMed Pharmaceuticals shares

There are currently 93,348 InMed Pharmaceuticals shares held short by investors – that's known as InMed Pharmaceuticals's "short interest". This figure is 397.4% up from 18,766 last month.

There are a few different ways that this level of interest in shorting InMed Pharmaceuticals shares can be evaluated.

InMed Pharmaceuticals's "short interest ratio" (SIR)

InMed Pharmaceuticals's "short interest ratio" (SIR) is the quantity of InMed Pharmaceuticals shares currently shorted divided by the average quantity of InMed Pharmaceuticals shares traded daily (recently around 93348). InMed Pharmaceuticals's SIR currently stands at 1. In other words for every 100,000 InMed Pharmaceuticals shares traded daily on the market, roughly 1000 shares are currently held short.

To gain some more context, you can compare InMed Pharmaceuticals's short interest ratio against those of similar companies.

• Tilray (APHA.US): 1.91
• Moderna (MRNA.US): 1.71
• Regeneron Pharmaceuticals (REGN.US): 2.22
• AbbVie (ABBV.US): 2.49

However InMed Pharmaceuticals's short interest can also be evaluated against the total number of InMed Pharmaceuticals shares, or, against the total number of tradable InMed Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case InMed Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 InMed Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0117% of the tradable shares (for every 100,000 tradable InMed Pharmaceuticals shares, roughly 12 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against InMed Pharmaceuticals.

Find out more about how you can short InMed Pharmaceuticals stock.

InMed Pharmaceuticals share dividends

We're not expecting InMed Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

• AbbVie (ABBV.US) (4.18% forward annual dividend yield)

Have InMed Pharmaceuticals's shares ever split?

InMed Pharmaceuticals's shares were split on a 1:33 basis on 5 July 2020. So if you had owned 33 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your InMed Pharmaceuticals shares – just the quantity. However, indirectly, the new 3200% higher share price could have impacted the market appetite for InMed Pharmaceuticals shares which in turn could have impacted InMed Pharmaceuticals's share price.

InMed Pharmaceuticals share price volatility

Over the last 12 months, InMed Pharmaceuticals's shares have ranged in value from as little as $2.38 up to $5.661. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InMed Pharmaceuticals's is 1.4309. This would suggest that InMed Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put InMed Pharmaceuticals's beta into context you can compare it against those of similar companies.

• Tilray (APHA.US): 2.6198
• Moderna (MRNA.US): 1.4749
• Regeneron Pharmaceuticals (REGN.US): 0.185
• AbbVie (ABBV.US): 0.8009

InMed Pharmaceuticals overview

InMed Pharmaceuticals Inc. , a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc.

Frequently asked questions

What percentage of InMed Pharmaceuticals is owned by insiders or institutions?
Currently 0.861% of InMed Pharmaceuticals shares are held by insiders and 6.337% by institutions. When does the fiscal year end for InMed Pharmaceuticals?
InMed Pharmaceuticals's fiscal year ends in June. Where is InMed Pharmaceuticals based?
InMed Pharmaceuticals's address is: 815 West Hastings Street, Vancouver, BC, Canada, V6C 1B4